ClinicalTrials.gg
RecruitingNCT06642857Updated Oct 15, 2024

Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.

An observational study in Advanced Gastric Carcinoma and Advanced Gastroesophageal Junction Adenocarcinoma, sponsored by Xiangdong Cheng. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Xiangdong Cheng · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Ages
18 Years to 75 Years
Sex
All
01

Study summary

In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.

Read the detailed description

Main objective: to extract and identify multi omics information tags related to the efficacy of immunotherapy for advanced gastric / gastroesophageal junction cancer

Secondary objective: to construct and validate the efficacy prediction model of chemotherapy combined with immunotherapy for gastric cancer, in order to optimize the scheme decision of advanced gastric cancer treatment

Exploratory purpose: to screen potential molecular markers / dominant flora for predicting the efficacy of immunotherapy in patients with advanced gastric / gastroesophageal junction cancer

02

Conditions studied

  • Advanced Gastric Carcinoma
  • Advanced Gastroesophageal Junction Adenocarcinoma

Keywords

  • Advanced Gastric Carcinoma
  • Advanced Gastroesophageal Junction Adenocarcinoma
  • Chemotherapy combined with immunotherapy
  • efficacy prediction
03

In context

Lead sponsor

Xiangdong Cheng is the lead sponsor of 7 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Eligibility criteria

Inclusion criteria:

  • Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or disease that cannot be resected
  • negative
  • Not received any anti-tumor treatment before.
  • After evaluation, the treatment plan is chemotherapy combined with immunotherapy.
  • Aged 18 to 75 years old, gender is not limited.
  • Expected survival time is greater than or equal to 3 months. Exclusion criteria:
  • Patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites.
  • Patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy.
  • Patients with severe infections.
  • Those with a history of mental illness cannot cooperate with the research.
  • Patients with severe heart, liver, kidney and other diseases.
  • Pregnant or lactating patients.
  • HER2 positive.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with advanced gastric cancer

    Advanced gastric cancer patients receiving chemotherapy combined with immunotherapy

    Other: Peripheral blood, tougue coating, saliva, and feces

Interventions

  • OtherPeripheral blood, tougue coating, saliva, and feces

    Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.

06

What researchers measure

Primary outcomes

  1. Objective Best Tumor Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: 12 months

  2. Overall Survival

    Overall survival is the duration from diagnosis to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: 60 months

Secondary outcomes

  1. Progression-free Survival

    The period from diagnosis until disease progression or death on study, whichever occurred first.

    Time frame: 36 months

Other outcomes

  1. Survival rate of 12 month

    The proportion of people who are still alive within 12 month from the diagnosis

    Time frame: 12 month from the diagnosis

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Xiangdong Cheng Xiangdong Cheng, PhD · Contactchengxd516@126.com · +0086-0571-88128041
    • Nannan Zhang Nannan Zhang, PhD · Contactnatilen@163.com · 18920166859
08

References and documents

Publications

  • Yuan L, Yang L, Zhang S, Xu Z, Qin J, Shi Y, Yu P, Wang Y, Bao Z, Xia Y, Sun J, He W, Chen T, Chen X, Hu C, Zhang Y, Dong C, Zhao P, Wang Y, Jiang N, Lv B, Xue Y, Jiao B, Gao H, Chai K, Li J, Wang H, Wang X, Guan X, Liu X, Zhao G, Zheng Z, Yan J, Yu H, Chen L, Ye Z, You H, Bao Y, Cheng X, Zhao P, Wang L, Zeng W, Tian Y, Chen M, You Y, Yuan G, Ruan H, Gao X, Xu J, Xu H, Du L, Zhang S, Fu H, Cheng X. Development of a tongue image-based machine learning tool for the diagnosis of gastric cancer: a prospective multicentre clinical cohort study. EClinicalMedicine. 2023 Feb 6;57:101834. doi: 10.1016/j.eclinm.2023.101834. eCollection 2023 Mar. PubMed 36825238 ↗
  • Li MY, Zhu DJ, Xu W, Lin YJ, Yung KL, Ip AWH. Application of U-Net with Global Convolution Network Module in Computer-Aided Tongue Diagnosis. J Healthc Eng. 2021 Nov 18;2021:5853128. doi: 10.1155/2021/5853128. eCollection 2021. PubMed 34840700 ↗
  • Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763. PubMed 36633525 ↗

Individual participant data

Plan to share: Undecided — We currently have no plans to share individual participant data (IPD) with other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Feb 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Oct 15, 2024
StartActual
Mar 25, 2024
Primary completionEst.
Feb 1, 2026
CompletionEst.
Feb 1, 2026
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642857
Lead sponsor
Xiangdong Cheng
Responsible party
Xiangdong Cheng (Professor, Zhejiang Cancer Hospital) — Sponsor-investigator
First posted
Oct 15, 2024
Start date
Mar 25, 2024
Primary completion
Feb 1, 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Oct 15, 2024

Study contacts

Xiangdong Cheng Cheng, PhD
Contact
Chengxd516@126.com
+0086-0571-88128041

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion